Advertisement
Advertisement

KURA

KURA logo

Kura Oncology, Inc.

10.36
USD
Sponsored
-0.03
-0.31%
Jul 27, 15:51 UTC -4
Open

KURA Earnings Reports

Positive Surprise Ratio

KURA beat 31 of 42 last estimates.

74%

Next Report

In 3 Days
Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$21.72M
/
-$0.89
Implied change from Q1 26 (Revenue/ EPS)
+18.94%
/
+7.23%
Implied change from Q2 25 (Revenue/ EPS)
+42.10%
/
+18.67%

Kura Oncology, Inc. earnings per share and revenue

On May 12, 2026, KURA reported earnings of -0.83 USD per share (EPS) for Q1 26, missing the estimate of -0.64 USD, resulting in a -28.56% surprise. Revenue reached 18.27 million, compared to an expected 18.88 million, with a -3.28% difference. The market reacted with a -2.07% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.89 USD, with revenue projected to reach 21.72 million USD, implying an increase of 7.23% EPS, and increase of 18.94% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
NovoCure Limited Ordinary Shares
Report Date
Jul 23, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.13
Surprise
+61.70%
logo
DBV Technologies S.A.
Report Date
Jul 16, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.60
Surprise
-494.06%
logo
argenx SE - ADR
Report Date
Jul 23, 2026 For Q2 26
Estimate
$6.29
Actual
$7.32
Surprise
+16.38%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
logo
VivoSim Labs, Inc. Common Stock
Report Date
Jul 14, 2026 For Q4 25
Estimate
-$0.19
Actual
-$2.21
Surprise
-1,040.35%
FAQ
For Q1 2026, Kura Oncology, Inc. reported EPS of -$0.83, missing estimates by -28.56%, and revenue of $18.27M, -3.28% below expectations.
The stock price moved down -2.07%, changed from $9.68 before the earnings release to $9.48 the day after.
The next earning report is scheduled for Jul 30, 2026.
Based on 10 analysts, Kura Oncology, Inc. is expected to report EPS of -$0.89 and revenue of $21.72M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement